View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 25, 2011

Bristol-Myers Squibb to Acquire Amira Pharmaceuticals

Bristol-Myers Squibb has signed a definitive agreement to acquire US-based Amira Pharmaceuticals for a price of $325m, with additional payments totalling $150m. Under the agreement, Bristol-Myers Squibb will acquire all of Amira's issued and outstanding shares of capital stock and stock

By cms admin

Bristol-Myers Squibb has signed a definitive agreement to acquire US-based Amira Pharmaceuticals for a price of $325m, with additional payments totalling $150m.

Under the agreement, Bristol-Myers Squibb will acquire all of Amira’s issued and outstanding shares of capital stock and stock equivalents.

Bristol-Myers Squibb will also secure Amira’s fibrosis programme, including lead asset AM152, and the pre-clinical autotaxin programme.

Bristol-Myers Squibb Research and Development executive vice president, chief scientific officer and president Elliott Sigal said the acquisition represents a targeted set of transactions designed to enrich the company’s pipeline with potential medicines to help patients in need.

The closing of the transaction is subject to customary regulatory approvals.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology